← Eichor
Study identifier: NCT07521137 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence

Condition: Candidiasis, Vulvovaginal  ·  Sponsor: Sano Chemicals Inc

PhasePhase 2
Planned participants36
Who can joinFemale, 18 Years to 65 Years
Healthy volunteersNo

About this study

A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of OCF001 Intravaginal Gel in Women with Acute Vulvovaginal Candidiasis

This description comes directly from the study's public registry record.

Talk to the study team

James Smith  ·  662-574-5957  ·  jsmith@sanochemicals.com

Always discuss trial participation with your own doctor first.

Locations (1)

UAB Sexual Health Research ClinicBirmingham, Alabama, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07521137